Letter to the Editor on the original article “A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia” by Bryant Al, et al. 2018
- 1 June 2020
- journal article
- letter
- Published by Elsevier in Leukemia Research
- Vol. 93, 106355
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemiaLeukemia Research, 2018
- Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialThe Lancet Haematology, 2017
- Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyLeukemia & Lymphoma, 2013
- Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of lifeLeukemia & Lymphoma, 2010
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993